Introduction {#s1}
============

Gastric cancer (GC) is the second leading cause of cancer-related deaths in men and women.[@R1] [@R2] Most patients are diagnosed with advanced stage disease with lymph node metastases already present, leading to a poor prognosis.[@R3] [@R4] Treatment options in patients with advanced GC are limited, but perioperative, adjuvant and palliative chemotherapy improves progression-free and overall survival.[@R5] Evidence is accumulating that patient prognosis and treatment response does not only depend on tumour stage but also on specific genotypic and phenotypic tumour characteristics. The advancements of targeted therapy provide compelling evidence that cancers of the same anatomic origin, for example, lung or colon, show great variability in their response rates to chemotherapies, necessitating a more in-depth phenotypic/genotypic classification before treatment. Recently, whole-genome sequencing and comprehensive molecular profiling of GC found subtype-specific genetic and epigenetic alterations with unique mutational signatures.[@R8] [@R9] A molecular classification of GC was proposed, which categorises four subtypes: Epstein--Barr virus (EBV)-positive, microsatellite instable (MSI), chromosomal instable and genomically stable GCs.[@R8] Genomically stable GCs are enriched for the diffuse phenotype and hotspot mutations of *RHOA.*[@R9] [@R10] Rho GTPases are small GTP/GDP-binding proteins that are found in all eukaryotes[@R11] and act as molecular switches by cycling from GTP-bound active to GDP-bound inactive state. Cycling is controlled by guanine nucleotide-exchange factors, the intrinsic GTPase activity, GTPase activating proteins and guanine nucleotide-dissociation inhibitors.[@R12] Rho GTPases play fundamental roles in cell migration, adhesion, cell survival, cell division, gene expression and vesicle trafficking,[@R13] and hence, tumour cell biology.[@R14] Interestingly, Rho/Rho-kinase inhibitors have been explored as putative therapeutic targets in diverse diseases.[@R15] In this study, we aimed to validate independently the prevalence and clinicopathological characteristics of *RHOA* mutant GCs in a Central European patient cohort.

Materials and methods {#s2}
=====================

Study population {#s2a}
----------------

From our archive, we retrieved patients who had undergone total or partial gastrectomy for adenocarcinomas of the stomach or esophagogastric junction. The patient characteristics are summarised in [table 1](#JCLINPATH2015202980TB1){ref-type="table"}. Date of patient death was obtained from the *Epidemiological Cancer Registry* of the state of Schleswig-Holstein, Germany. Follow-up data were retrieved from hospital records and general practitioners.

###### 

Clinicopathological patient characteristics of the gastric cancer cohort and correlation with *RHOA* genotype

  Characteristic         Valid (n)                    Total         *RHOA* wildtype (n (%))   *RHOA* mutation (n (%))   p Value
  ---------------------- ------------ --------------- ------------- ------------------------- ------------------------- ----------
  Gender                 415          Female          166 (40.0)    157 (94.6)                9 (5.4)                   0.199\*
  Male                   249 (60.0)   242 (97.2)      7 (2.8)                                                           
  Age                    402          ≤68 years       198 (49.3)    190 (96.0)                8 (4.0)                   1.000\*
  \>68 years             204 (50.7)   196 (96.1)      8 (3.9)                                                           
  Laurén phenotype       415          Intestinal      210 (50.6)    206 (98.1)                4 (1.9)                   0.110\*
  Diffuse                134 (32.3)   125 (93.3)      9 (6.7)                                                           
  Mixed                  27 (6.5)     27 (96.4)       1 (3.6)                                                           
  Unclassified           41 (9.9)     41 (95.3)       2 (4.7)                                                           
  Mucin phenotype        365          Intestinal      102 (27.9)    99 (97.1)                 3 (2.9)                   0.753\*
  Gastric                57 (15.6)    55 (96.5)       2 (3.5)                                                           
  Mixed                  146 (37.3)   139 (95.2)      7 (4.8)                                                           
  Unclassified           60 (16.4)    59 (98.3)       1 (1.7)                                                           
  Localisation           415          Proximal        127 (30.6)    124 (97.6)                3 (2.4)                   0.410\*
  Distal                 288 (69.4)   275 (95.5)      13 (4.5)                                                          
  T-category             415          T1a/b           47 (11.3)     44 (93.6)                 3 (6.4)                   0.086†
  T2                     49 (11.8)    46 (93.9)       3 (6.1)                                                           
  T3                     169 (40.7)   162 (95.9)      7 (4.1)                                                           
  T4a/b                  150 (36.1)   147 (98.0)      3 (2.0)                                                           
  T-category (grouped)   415          T1/T2           96 (22.6)     90 (93.8)                 6 (6.2)                   0.221\*
  T3/T4                  319 (77.4)   309 (96.9)      10 (3.1)                                                          
  N-category             413          N0              116 (28.1)    111 (95.7)                5 (4.3)                   0.786†
  N1                     58 (14.0)    56 (96.6)       2 (3.4)                                                           
  N2                     69 (16.7)    66 (95.7)       3 (4.3)                                                           
  N3/a/b                 170 (41.2)   164 (96.5)      6 (3.5)                                                           
  L-category             403          L0              186 (46.2)    178 (95.7)                8 (4.3)                   0.802\*
  L1                     217 (53.8)   209 (96.3)      8 (3.7)                                                           
  M-category             415          M0              343 (82.7)    327 (95.3)                16 (4.7)                  0.086\*
  M1                     72 (17.3)    72 (100)        0 (0)                                                             
  V-category             402          V0              353 (87.8)    339 (96.0)                14 (4.0)                  1.000\*
  V1                     49 (12.2)    47 (95.9)       2 (4.1)                                                           
  Stage (7th edn)        407          IA              35 (8.6)      33 (94.3)                 2 (5.7)                   0.127†
  IB                     29 (7.1)     27 (93.1)       2 (6.9)                                                           
  IIA                    52 (12.8)    51 (98.1)       1 (1.9)                                                           
  IIB                    43 (10.6)    41 (95.3)       2 (4.7)                                                           
  IIIA                   46 (11.3)    42 (91.3)       4 (8.7)                                                           
  IIIB                   70 (17.2)    67 (95.7)       3 (4.3)                                                           
  IIIC                   60 (14.7)    58 (96.7)       2 (3.3)                                                           
  IV                     72 (17.7)    72 (100)        0 (0)                                                             
  LNR (median=0.214)     407          ≤0.214          204 (50.1)    197 (96.6)                7 (3.4)                   0.622\*
  \>0.214                203 (49.9)   194 (95.6)      9 (4.4)                                                           
  Tumour grade           405          G1/G2           91 (22.5)     90 (98.9)                 1 (1.1)                   0.136\*
  G3/G4                  314 (77.5)   299 (95.2)      15 (4.8)                                                          
  Resection margin       394          R0              346 (87.8)    335 (96.8)                11 (3.2)                  0.664\*
  R1/R2                  48 (12.2)    46 (95.8)       2 (4.2)                                                           
  E-Cadherin‡            382          Negative        280 (73.3)    268 (95.7)                12 (4.3)                  0.768\*
  Positive               102 (26.7)   99 (97.1)       3 (2.9)                                                           
  β-Catenin‡             384          Negative        213 (55.5)    202 (94.8)                11 (5.2)                  0.191\*
  Positive               171 (44.5)   167 (97.7)      4 (2.3)                                                           
  Lysozyme‡              384          Negative        182 (47.4)    179 (98.4)                3 (1.6)                   0.035\*
  Positive               202 (52.6)   190 (94.1)      12 (5.9)                                                          
  Survival (months)      402          Events (Dead)   318 (79.1)    305 (95.9)                13 (4.1)                  0.457^§^
  Alive                  84 (20.9)    81 (96.4)       3 (3.6)                                                           
  Median survival                     14.6±1.1        11.6±2.4                                                          
  95% CI                              12.4 to 16.8    6.9 to 16.4                                                       

\*Fisher\'s exact test.

†Kendall's tau test.

‡Dichotomized at the median.

§Log-rank test.

Study inclusion and exclusion criteria {#s2b}
--------------------------------------

Patients were included when (1) histology confirmed an adenocarcinoma and (2) the date of death or survival data were available. Patients were excluded when (1) histology identified a tumour type other than adenocarcinoma, (2) patients had previously undergone a resection of a Billroth-II stomach with cancer in the gastric remnant, (3) date of patient death or survival data had not been recorded and (4) perioperative chemotherapy was administered.

Histology and TNM classification {#s2c}
--------------------------------

Tissue samples had been fixed in formalin and embedded in paraffin (FFPE). Sections were stained with H&E. Tumours were classified according to Laurén.[@R16] Pathological tumour, node, metastases (pTNM) stage was determined according to the seventh edition of the Union for International Cancer Control UICC guidelines.[@R17] Tissue micro arrays were generated as described previously.[@R18]

DNA sequence analysis {#s2d}
---------------------

Genomic DNA was extracted from FFPE tissue using the QIAamp DNA mini kit (Qiagen, Hilden, Germany) following the manufacturer\'s instructions. Tissue sections were manually microdissected prior to DNA isolation to enrich tumour cells (\>80%). For mutational analysis of exon 2 and 3 of *RHOA*, a 282 and 215 bp fragment were amplified by PCR using the primers 5′-*caggaaacagctatgac*[agctctaattctctacatgctcc]{.smallcaps}-3′ (sense) and 5′-*gtaaaacgacggccagt*[cctatgacttcttgtgcattgc]{.smallcaps}-3′ (antisense) for exon 2 and the primers 5′-*gtaaaacgacggccagt*[actagctacacaggcagtgacaa]{.smallcaps}-3′ (sense) and 5′-*caggaaacagctatgac*[gtggggggattaaccttgca]{.smallcaps}-3′ (antisense) for exon 3 (universal *M13 sequencing primer* binding sites were added to the 5′-end of the PCR primers). PCR products were purified using the QIAquick 96 PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced by dye terminator cycle sequencing (BigDye Terminator v1.1 Cycle Sequencing kit, Applied Biosystems, Darmstadt, Germany) with universal M13 primers. The sequencing products were purified using the DyeEx 96 Kit (Qiagen) and analysed on a Genetic Analyzer 3500 (Applied Biosystems).

Assessment of phenotype, genotype and infectious status {#s2e}
-------------------------------------------------------

The *KRAS-* (codon 12 and 13), *PIK3CA-* (exon 9 and 20) genotype, the mucine-, E-cadherin- and β-catenin-immunophenotype, as well as the *Helicobacter pylori*, *Epstein--Barr virus*, microsatellite and Her2/neu status were assessed as described in detail previously (see online supplementary materials and methods).[@R18] [@R19]

Statistical methods {#s2f}
-------------------

Statistical analyses were performed using SPSS V.20.0 (IBM Corporation). For continuous variables, cases were divided into two groups by splitting at the median value. Median overall survival was determined using the Kaplan--Meier method, and the log-rank test was used to determine significance. For comparison purposes, the median survival time, its SD and 95% CI were calculated. The significance of correlation between clinicopathological variables was tested using Fisher's exact test. For variables of ordinal scale (T-category, N-category, tumour stage), we applied Kendall's tau test instead. A p≤0.05 was considered statistically significant. The p values are given unadjusted.

Results {#s3}
=======

GC cohort {#s3a}
---------

A total of 415 patients fulfilled all study criteria, including 249 (60.0%) men and 166 women (40.0%; [table 1](#JCLINPATH2015202980TB1){ref-type="table"}). The median patient age was 68 years. According to Laurén, an intestinal-type GC was found in 210 (50.6%), a diffuse type in 134 (32.3%), a mixed type in 27 (6.5%) and an unclassifiable type in 41 (9.9%) patients. According to the mucin-phenotype, 102 (27.9%) GCs were of the intestinal, 57 (15.6%) of the gastric, 146 (37.3%) of the mixed and 60 (16.4%) of the unclassified type ([table 1](#JCLINPATH2015202980TB1){ref-type="table"}). In total, 202 (52.6%) GCs were categorised as lysozyme-positive, and 280 (73.3%) as E-cadherin-negative and 213 (55.5%) as β-catenin-negative. Non-neoplastic mucosa was available from 351 patients and was screened for *H. pylori*. Fifty-three (15.1%) patients had a persistent infection with *H. pylori*. EBV-RNA was found in 15 (3.7% of 402 valid results) GCs.

Prevalence of *RHOA* mutation {#s3b}
-----------------------------

Sixteen (3.9%) tumours had an *RHOA* mutation in exon 2 (12 (75%); p.R5Q, p.G17E, p.G17Efs\*24, p.L22R, p.V24F, p.T37A and p.Y42C) or 3 (4 (25%); p.L57V and p.L69R) ([table 2](#JCLINPATH2015202980TB2){ref-type="table"}). Fourteen tumours had a single-point mutation and two harboured a deletion/insertion mutation. A transition (A\>G or G\>A) was found in nine cases, which was restricted to exon 2. A transversion (G\>T or T\>G) was present in five cases being more prevalent in exon 3 ([table 2](#JCLINPATH2015202980TB2){ref-type="table"}).

###### 

Clinicopathological characteristics and genotype of the *RHOA* mutant gastric cancers

  Case number   Gender   Age at diagnosis   Tumour localisation   Laurén phenotype   T-category   N-category   M-category   UICC stage   Tumour grade   *KRAS codon 12 and 13*   *PIK3CA exon 9*   *PIK3CA exon 20*   MSI status      EBV status   *Helicobacter pylori* status   *RHOA mutation*                *RHOA exon*   *RHOA substitution mutation*   *Functional region---interaction with*
  ------------- -------- ------------------ --------------------- ------------------ ------------ ------------ ------------ ------------ -------------- ------------------------ ----------------- ------------------ ------------ -- ------------ ------------------------------ ------------------------------ ------------- ------------------------------ ----------------------------------------
  1             F        44                 Distal                Diffuse            T1b          N0           M0           IA           G2             WT                       WT                WT                 MSS             −            mv                             c.125A\>G, p.Y42C              2             Transition                     Effector domain
  2             F        38                 Distal                Diffuse            T3           N1           M0           IIIA         G3             WT                       WT                WT                 MSS             −            −                              c.169T\>G, p.L57V              3             Transversion                   PKN/PRK1
  3             F        66                 Distal                Diffuse            T1a          N0           M0           IA           G3             WT                       WT                WT                 MSS             −            −                              c.169T\>G, p.L57V              3             Transversion                   PKN/PRK1
  4             F        80                 Distal                Diffuse            T4a          N2           M0           IIIB         G3             WT                       WT                WT                 MSS             −            −                              c.65_66delinsGT, p.L22R        2             Deletion/Insertion             --
  5             F        68                 Distal                Diffuse            T4a          N3a          M0           IIIC         G3             WT                       WT                WT                 MSS             −            mv                             c.206T\>G, p.L69R\#            3             Transversion                   --
  6             F        69                 Proximal              Diffuse            T2           N0           M0           IB           G3             WT                       WT                WT                 MSS             −            −                              c.125A\>G, p.Y42C              2             Transition                     Effector domain
  7             M        90                 Proximal              Diffuse            T3           N3           M0           IIIB         G3             WT                       WT                WT                 MSS             −            −                              c.50G\>A, p.G17E               2             Transition                     GTP
  8             M        68                 Proximal              Diffuse            T3           N2           M0           IIIA         G3             WT                       WT                WT                 MSS             −            −                              c.14G\>A, p.R5Q                2             Transition                     --
  9             M        62                 Distal                Diffuse            T3           N2           M0           IIIA         G3             WT                       WT                WT                 MSS             −            mv                             c.109A\>G, p.T37A\#            2             Transition                     Effector domain
  10            F        72                 Distal                Intestinal         T3           N3a          M0           IIIB         G3             WT                       WT                WT                 MSS             −            −                              c.125A\>G, p.Y42C              2             Transition                     Effector domain
  11            M        84                 Distal                Intestinal         T2           N0           M0           IB           G3             WT                       WT                WT                 MSS             −            −                              c.125A\>G, p.Y42C              2             Transition                     Effector domain
  12            M        85                 Distal                Intestinal         T2           N3a          M0           IIIA         G3             WT                       WT                WT                 MSS             −            −                              c.70G\>T, p.V24F               2             Transversion                   --
  13            M        66                 Distal                Intestinal         T3           N0           M0           IIA          G3             WT                       WT                WT                 MSI             −            \+                             c.50delinsAA, p.G17Efs\*24\#   2             Deletion/Insertion             GTP
  14            F        80                 Distal                Unclassified       T3           N1           M0           IIB          G3             WT                       WT                WT                 MSS             −            −                              c.169T\>G, p.L57V              3             Transversion                   PKN/PRK1
  15            F        58                 Distal                Unclassified       T1b          N3b          M0           IIB          G3             WT                       WT                WT                 MSS             −            −                              c.125A\>G, p.Y42C              2             Transition                     Effector domain
  16            M        59                 Distal                Mixed              T4b          N3a          M0           IIIC         G3             WT                       MUT               WT                 MSS             \+           \+                             c.14G\>A, p.R5Q                2             Transition                     --

\#, hitherto unreported mutations; −, negative; +, positive; EBV, Epstein--Barr virus; GTP, guanosine triphosphate; MSI, microsatellite instable; MSS, microsatellite stable; mv, missing value; PKN/PRK1, protein kinase N1; UICC, Union for International Cancer Control; WT, wildtype.

Correlation of *RHOA* mutation with clinicopathological patient characteristics {#s3c}
-------------------------------------------------------------------------------

*RHOA* mutation was more prevalent in women (5.4% vs 2.8%), distal GCs (4.5% vs 2.4%) and in poorly differentiated GCs (G3/G4; 4.8% vs 1.1%). Interestingly, *RHOA* mutant GCs usually showed a lower T-category. However, neither of these findings was statistically significant ([table 1](#JCLINPATH2015202980TB1){ref-type="table"}).

According to Laurén, nine (56%) *RHOA* mutant GCs had a diffuse, four (25%) an intestinal, two (13%) an unclassified and one (6%) a mixed phenotype ([figure 1](#JCLINPATH2015202980F1){ref-type="fig"}). *RHOA* mutant GCs were most commonly lysozyme-immunopositive (80%), and E-cadherin-immunonegative (80%) and β-catenin- (73%) immunonegative. *KRAS* and *RHOA* mutations were mutually exclusive. A single case showed both a *RHOA* and a *PIK3CA* mutation. MSI and EBV were found each in a single case with *RHOA* mutation.

![Histomorphology of gastric cancers with *RHOA* mutation. *RHOA* mutant gastric cancers were most commonly of diffuse type according to Laurén (A). Intestinal (B), unclassified (C) and mixed (D) phenotype were found in a minority of the cases. H&E; original magnification 200-fold.](jclinpath-2015-202980f01){#JCLINPATH2015202980F1}

No significant difference was found in the overall survival between *RHOA* mutant and wildtype GCs ([figure 2](#JCLINPATH2015202980F2){ref-type="fig"}).

![Patients' survival. Kaplan--Meier curves depicting patients' survival according to *RHOA* genotype. mut, mutant; wt, wildtype.](jclinpath-2015-202980f02){#JCLINPATH2015202980F2}

Discussion {#s4}
==========

Hitherto, oncological treatment of malignant epithelial tumours largely depended on their anatomical origin. With the advancements of targeted therapy, it became increasingly evident that cancers of the same anatomical origin show great variability in their response rates to chemotherapies, necessitating a more in-depth phenotypic/genotypic classification prior to treatment. While this has led to major improvements in few cancer types, it is still in its infancies in GC. Except for *HER2* status, no other molecular (ie, diagnostic, prognostic or predictive) classifier has reached clinical practice despite evidence that response to chemotherapy may depend on genotypical/phenotypical characteristics of GC: using gene expression profiling, Tan *et al*[@R20] identified intrinsic subtypes of GC (intestinal vs diffuse type) that respond differently to 5-fluouracil, cisplatin and oxaliplatin. Recently, whole-genome sequencing and comprehensive molecular profiling proposed four molecular subtypes of GC,[@R8] of which the genomically stable subtype was specifically enriched for the diffuse phenotype and hotspot mutations of RHOA.[@R9] [@R10]

Here we aimed to validate the occurrence, phenotype and clinicopathological characteristics of *RHOA* mutant GCs in an independent Central European GC cohort. Sixteen (3.9%) tumours of our cohort had a *RHOA* mutation. The prevalences reported hitherto ranged from 6%[@R8] [@R10] to 25.3%[@R9] and largely depend on the composition of the cohorts, being higher in cohorts with a greater number of diffuse-type GCs. As yet, our study comprises the only single-centre GC cohort tested for *RHOA* mutation and the largest GC patient series: *The Cancer Genome Atlas Research Network*[@R8] studied 295 patients, Wang *et al*[@R10] 100 patients and Kakiuchi *et al*[@R9] 87 patients. Five mutations of our cohort had been described previously, that is, p.R5Q, p.G17E, p.L22R, p.Y42C, p.L57 and p.L69R.[@R8] However, we also found mutations hitherto unreported in GC including a deletion-insertion mutation in exon 2, that is, p.G17Efs\*24, p.V24F and p.T37A ([table 2](#JCLINPATH2015202980TB2){ref-type="table"}). The mutations affect the functional domains of RHOA, such as the GTP-binding sites and the effector binding region and may have different effects.[@R8] p.Tyr42Cys and p.Gly17Glu were considered as *gain-of-function* mutations, which may provide strong growth advantage in diffuse-type GC progression.[@R9] To the contrary, Wang *et al*[@R10] provided evidence that p.Tyr42Cys and p.Leu57Val lead to defective signalling, promoting escape from anoikis. In order to support any of these contentions, we correlated the presence of *RHOA* mutations with various clinicopathological patient characteristics. In accordance with previous observations, *RHOA* mutation was more prevalent in women, distal GCs and in poorly differentiated GCs.[@R10] Interestingly, *RHOA* mutant GCs usually showed a lower T-category and no distant metastases, seemingly contradicting a growth advantageous effect. However, neither of these findings was significant ([table 1](#JCLINPATH2015202980TB1){ref-type="table"}) and larger patient cohorts may be needed to demonstrate a putative effect on local tumour growth or tumour spread.

Previously, Tan *et al*[@R20] described 171 genes, which separate intestinal-type from diffuse-type GC. Lysozyme was among the genes highly significantly differentially expressed and was selected by us as another putative immunohistochemical marker between intestinal-type and diffuse-type GC.[@R20] While lysozyme expression correlated significantly with *RHOA* genotype, immunostaining, in general, was unsuitable to detect *RHOA* mutant GCs as only a small proportion of E-cadherin-immunonegative /β-catenin-immunonegative and lysozyme-immunopositive GCs harboured *RHOA* mutations (\<6%; [table 1](#JCLINPATH2015202980TB1){ref-type="table"}).

Rho GTPases have been associated with the alterations of *P53*, *KRAS* and *APC,* as well as KRAS/PIK3CA-signalling in colon cancer, lung cancer and liver carcinogenesis.[@R14] [@R21] Therefore, we were interested to compare the *RHOA* genotype with other genetic alterations found previously in our cohort[@R18]: *KRAS* and *RHOA* mutations were mutually exclusive, lending support to the hypothesis that the KRAS--RHOA axis may be a putative signalling axis in GC as it has recently been shown in non-small cell lung cancer.[@R22] A single case showed both an *RHOA* and a *PIK3CA* mutation. However, the overall prevalences of *KRAS*, *PIK3CA* and *RHOA* mutations are low in our GC cohort (each below 5%) and no firm conclusions can be drawn.

The whole-genome sequencing and comprehensive molecular profiling classified EBV-positive and MSI GCs as distinct molecular subtypes. Interestingly, MSI and EBV were found each in a single case with *RHOA* mutation. Similar findings were made by others: a minority of *RHOA*-mutant GCs can be MSI or EBV-positive.[@R8] Thus, molecular subtypes may overlap in a single patient. However, the vast majority of *RHOA* mutant GCs was microsatellite stable (93%) and EBV-negative (94%), confirming previous findings.[@R8] No significant difference was found in the overall survival between *RHOA* mutant and wildtype GCs ([figure 2](#JCLINPATH2015202980F2){ref-type="fig"}), again raising doubt about a significant effect on tumour progression. In this respect, it is interesting to note that 17 patients of our cohort, commonly showing an intestinal-type GC, carried a *KRAS* mutation.[@R18] Thus, *RHOA* and *KRAS* mutation are not only mutually exclusive but are linked also to different phenotypes. In summary, our study confirms the occurrence and clinicopathological characteristics of *RHOA hotspot* mutations in an independent Central European patient cohort. Currently, we cannot confirm the prognostic or growth advantageous effect of *RHOA* mutations in GC and further studies into this topic are warranted. Take home messages*RHOA* hotspot mutations are rare and diverse in gastric cancer.*RHOA* mutations are more prevalent in women, distal and poorly differentiated gastric cancers.No significant difference was found in the overall survival between *RHOA* mutant and wildtype gastric cancers.RHOA- and KRAS mutations are mutually exclusive. *RHOA* mutations may occur occasionally in microsatellite instable or Epstein-Barr-virus-positive gastric cancers.
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